A carregar...
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
BACKGROUND: On the basis of data from a phase 2 trial that compared the checkpoint inhibitor ipilimumab at doses of 0.3 mg, 3 mg, and 10 mg per kilogram of body weight in patients with advanced melanoma, this phase 3 trial evaluated ipilimumab at a dose of 10 mg per kilogram in patients who had unde...
Na minha lista:
| Publicado no: | N Engl J Med |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5648545/ https://ncbi.nlm.nih.gov/pubmed/27717298 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1611299 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|